Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Phase 2, Responsive Adaptive Randomization Study of ORP-101 in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT04129619 is registered in ClinicalTrials.gov with OrphoMed, Inc. as lead sponsor.

NCT NCT04129619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04129619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Phase 2, Responsive Adaptive Randomization Study of ORP-101 in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Lead sponsor
OrphoMed, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 22, 2019
Completion date
October 4, 2021
Enrollment
321 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea